Case Control Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2021; 9(36): 11156-11164
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11156
Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
En-Wen Mao, Xue-Bing Cheng, Wen-Chao Li, Cheng-Xia Kan, Na Huang, Hong-Sheng Wang, Ning-Ning Hou, Xiao-Dong Sun
En-Wen Mao, Cheng-Xia Kan, Xiao-Dong Sun, Department of Endocrinology and Metabolism, Clinical Research Center, The Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China
Xue-Bing Cheng, Wen-Chao Li, Na Huang, Hong-Sheng Wang, Ning-Ning Hou, Department of Endocrinology and Metabolism, The Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China
Author contributions: Mao EW and Cheng XB performed the majority of experiments and wrote the manuscript, contributing equally to this article; Hou NN and Sun XD designed the study and corrected the manuscript; Li WC, Kan CX, Huang N, and Wang HS were involved in the sample collected and analytical tools.
Supported by National Natural Science Foundation of China, No. 81870593; Natural Science Foundation of Shandong Province of China, No. ZR2020MH106; Medical Health Science and Technology Project of Shandong Province, No. 202003060396 and No. 202003060400; and Quality Improvement of Postgraduate Education in Shandong Province, No. SDYAL19156.
Institutional review board statement: The study was approved by the Medical Ethics Committee of Affiliated Hospital of Weifang Medical University.
Informed consent statement: Informed consent was obtained prior to enrollment.
Conflict-of-interest statement: The authors have nothing to disclose.
Data sharing statement: The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Dong Sun, MD, PhD, Associate Chief Physician, Department of Endocrinology and Metabolism, Clinical Research Center, The Affiliated Hospital of Weifang Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China.xiaodong.sun@wfmc.edu.cn
Received: July 12, 2021
Peer-review started: July 12, 2021
First decision: September 5, 2021
Revised: September 6, 2021
Accepted: November 14, 2021
Article in press: November 14, 2021
Published online: December 26, 2021
Processing time: 164 Days and 13.1 Hours
Core Tip

Core Tip: This study demonstrated that serum Sestrin2 is increased in patients with type 2 diabetes but reduced in type 2 diabetic patients with diabetic peripheral neuropathy. Sestrin2 may be a novel modulatory factor for metabolic disturbances in diabetes complications.